Your browser doesn't support javascript.
loading
Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma.
Pugalenthi, Amudhan; Mojica, Kelly; Ady, Justin W; Johnsen, Clark; Love, Damon; Chen, Nanhai G; Aguilar, Richard J; Szalay, Aladar A; Fong, Yuman.
Afiliación
  • Pugalenthi A; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Mojica K; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ady JW; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Johnsen C; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Love D; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chen NG; Genelux Corporation, San Diego Science Center, San Diego, CA, USA.
  • Aguilar RJ; Department of Radiation Medicine and Applied Sciences, Rebecca & John Moores Comprehensive Cancer Center, University of California, San Diego, CA, USA.
  • Szalay AA; Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
  • Fong Y; Department of Virology, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Cancer Gene Ther ; 22(12): 591-6, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26584530
Although early stage cholangiocarcinoma (CC) can be cured by surgical extirpation, the options for treatment of advanced stage CC are very few and suboptimal. Oncolytic virotherapy using replication-competent vaccinia virus (VACV) is a promising new strategy to treat human cancers. The ability of oncolytic VACV GLV-1h68 to infect, replicate in, and lyse three human CC cell lines was assayed in vitro and in subcutaneous flank xenografts in athymic nude mice. In this study, we have demonstrated that GLV-1h68 effectively infects and lyses three CC cell lines (KMC-1, KMBC, and KMCH-1) in vitro. Expression of the viral marker gene ruc-gfp facilitated real-time monitoring of infection and replication. Furthermore in athymic nude mice, a single dose of GLV-1h68 significantly suppressed tumor growth. The treatment was well tolerated in all animals. Recombinant VACV GLV-1h68 has significant oncolytic ability against CC both in vitro and in vivo. GLV-1h68 has the potential to be used clinically as a therapeutic agent against CC.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus Vaccinia / Neoplasias de los Conductos Biliares / Colangiocarcinoma / Viroterapia Oncolítica / Vectores Genéticos Límite: Animals / Humans Idioma: En Revista: Cancer Gene Ther Asunto de la revista: GENETICA MEDICA / NEOPLASIAS / TERAPEUTICA Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus Vaccinia / Neoplasias de los Conductos Biliares / Colangiocarcinoma / Viroterapia Oncolítica / Vectores Genéticos Límite: Animals / Humans Idioma: En Revista: Cancer Gene Ther Asunto de la revista: GENETICA MEDICA / NEOPLASIAS / TERAPEUTICA Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido